ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study

Study limitation reported by the research below: “Patients were not stratified by age subgroup within 'paediatric,' so it is unclear how findings apply to younger children vs. adolescents specifically.”

Papers